BCL2L1 and cancer: Bifunctional ASO-based exon skipping was first demonstrated for diminishing the bcl-xL/bcl-xS ratio in cultured cancer cells by carrying the binding sites for hnRNP A1/A2 in the SF recruiting part [59].